Hims & Hers
36 articles on Hims & Hers, written by Shotlee and medically reviewed for clinical accuracy.
Hims & Hers Downgrade: What It Means for GLP-1 Weight Loss Access
Bank of America cuts Hims & Hers price target as the telehealth giant pivots from compounded GLP-1s to branded alternatives. Here is what this shift means for patients.
8 min read
Hims & Hers Q1 Earnings: What It Means for GLP-1 Access & Weight Loss
Hims & Hers reports Q1 results. See how financial growth and regulatory shifts affect patient access to semaglutide, tirzepatide, and peptide therapy.
7 min read
FDA Proposes Curbs on Compounding Weight-Loss Drugs
The U.S. Food and Drug Administration (FDA) has proposed a significant change that could reshape the landscape of weight-loss drug accessibility. By suggesting the exclusion of key active ingredients from the list of drugs that outsourcing facilities can compound in bulk, the FDA aims to curb large-scale, unauthorized production of popular medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).
7 min read
RFK Jr.'s Peptide Policy Could Boost Hims & Hers GLP-1 Shift
Shares of Hims & Hers surged after HHS Secretary RFK Jr. revealed FDA plans to review peptides for compounding under the 503A bulk list. This comes as the telehealth leader evolves its high-margin compounded GLP-1 business toward branded options and new peptide therapies. CEO Andrew Dudum and CMO Dr. Patrick Carroll highlight the potential for regulated, physician-led peptide access.
6 min read
Time for Guardrails on GLP-1 Compounding: Safety Risks Exposed
America faces a crisis in unregulated compounded GLP-1 drugs, with FDA reporting 1,150 adverse events including hospitalizations and deaths. Exploiting shortages of semaglutide and tirzepatide, compounders flood the market with untested products, misleading consumers. Now, with the SAFE Drugs Act and FDA crackdowns, it's time to restore safety standards.
4 min read
Entrepreneur Uses AI to Build $1B Telehealth Company on GLP-1 Drugs
Matthew Gallagher, a 41-year-old LA entrepreneur, turned $20,000 into a nearly $2 billion telehealth empire with AI alone. Medvi sells GLP-1 drugs like Ozempic at $300 versus $1,000 retail, serving 250,000 customers. But rapid growth sparks debates on legality and fake ads.
5 min read
Hims & Hers Surges After RFK Jr. Pushes Peptide Access on Joe Rogan
Hims & Hers shares surged Monday after HHS Secretary Robert F. Kennedy Jr. expressed urgency on the Joe Rogan Experience to make 14 peptides more accessible. He highlighted FDA's review of the science behind these GLP-1 active ingredients for diabetes and weight loss. This could signal easing regulatory headwinds for telehealth providers like Hims.
5 min read
Peptide Gold Rush: Deregulation Set to Supercharge Shadow Industry
Peptides, once a Silicon Valley biohacking secret, are exploding in popularity—search interest now tops Ozempic. With RFK Jr. poised to reverse FDA restrictions, compounding pharmacies and telehealth platforms are racing to supply them legally. This could propel the $52B peptide market to $87B by 2035.
5 min read
Novo Nordisk's FDA-Approved GLP-1s Now on Hims & Hers
Hims & Hers Health, Inc. has partnered with Novo Nordisk to bring a broad assortment of FDA-approved GLP-1 medications to eligible customers, including the groundbreaking Wegovy® pill. This collaboration simplifies access with affordable prices, expanded doses, and diverse delivery methods. As the largest global consumer health platform for these approved meds, Hims & Hers is transforming weight management options.
4 min read
Hims & Hers Stock: Costly Wegovy Deal Challenges
Hims & Hers has resolved its dispute with Novo Nordisk, shifting to official weight loss drugs like Wegovy over controversial compounded GLP-1 alternatives. This brings legal clarity but slams profitability with higher costs and a cautious Q1 2026 revenue outlook of $600-625 million. With 2.5 million subscribers, can the stock rebound amid debt and investigations?
4 min read
Hims & Hers Opens $149 Wegovy & Ozempic Waitlist via Novo Deal
Hims & Hers Health (NYSE: HIMS) is now offering a waitlist for affordable branded Wegovy and Ozempic at $149, thanks to a new Novo Nordisk deal. This expands access to these popular GLP-1 weight-loss drugs amid high demand. Meanwhile, HIMS stock shows short-term rebound potential in a downtrend—dive into the technicals and analyst views.
5 min read
The Himsification of Medicine: Super Bowl Ad & Semaglutide Clash
Hims & Hers made waves with a Super Bowl ad promoting preventive care through tailored prescriptions and peptides for everyday Americans. But announcing compounded oral semaglutide triggered an FDA investigation and a swift lawsuit from Novo Nordisk. The quick settlement highlights battles over GLP-1 access and drug pricing.
4 min read
Hims & Hers, Novo Nordisk End Lawsuit, Collaborate on Wegovy Sales
In a surprise turn, Novo Nordisk is dropping its lawsuit against Hims & Hers Health, paving the way for branded Wegovy and Ozempic sales on the telehealth platform. This follows Hims' brief plan for cheaper compounded versions and FDA warnings on shortages. Patients gain better access to approved GLP-1 medications.
5 min read
Novo, Hims End GLP-1 Feud, Partner Again on Wegovy
The months-long GLP-1 feud between Novo Nordisk and Hims & Hers Health is over, with a new partnership to sell Wegovy via Hims' telehealth platform expected Monday. Following a recent lawsuit over copycat drugs, shares surged: Hims nearly 40%, Novo 2% after-hours. Analysts call it a surprise positive for expanded market reach.
5 min read
Aspen Pharmacare Targets Semaglutide Generic Approval in Canada by September
Aspen Pharmacare Holdings Ltd. is aiming for regulatory approval of its copycat semaglutide version in Canada by September, positioning itself as a first-mover. CEO Stephen Saad shared this timeline in a recent interview, highlighting Canada's role as a benchmark for other nations. This development could enhance affordability of GLP-1 therapies like Ozempic.
5 min read
Experts on Hims & Hers' $1.15B Eucalyptus Acquisition
Hims & Hers is acquiring Australian telehealth firm Eucalyptus for $1.15 billion to fuel global growth amid U.S. regulatory scrutiny over compounded GLP-1s. Experts call it a smart diversification move that complements weight loss and wellness services. This expansion could reshape access to personalized care worldwide.
5 min read
US May Fine Hims for Brief Wegovy Compounded Launch
Hims & Hers briefly launched a $49 compounded version of Novo Nordisk's Wegovy, prompting swift FDA backlash and a DOJ referral. Experts say the US could impose fines or injunctions for violating drug laws, though Hims' quick retreat might limit action. This highlights tensions between compounded GLP-1s and approved weight-loss drugs amid surging demand.
5 min read
Hims & Hers GLP-1 Pill Launch Backfires, Fuels Compounder Crackdown
Hims & Hers aimed to disrupt the GLP-1 market with a cheap oral semaglutide pill, but faced swift FDA backlash and a patent lawsuit from Novo Nordisk. The retreat highlights regulatory risks for compounders as branded supplies stabilize. This analysis reveals challenges in oral GLP-1 production and future paths for telehealth weight loss offerings.
6 min read
Lilly's $1.5B Orforglipron Inventory Grows Ahead of FDA Obesity Nod
Eli Lilly is stockpiling $1.5 billion worth of its oral obesity drug orforglipron to avoid the supply shortages that hampered early GLP-1 launches. With an expected FDA decision on April 10, the company aims for a swift global rollout against Novo Nordisk's Wegovy pill. This strategic move signals big changes in accessible weight loss therapy.
5 min read
Knockoff GLP-1 Market Still the Wild West After Hims Fiasco
Telehealth giant Hims & Hers stirred controversy by launching a cheap compounded version of Novo Nordisk's Wegovy pill, only to yank it days later amid FDA crackdowns and lawsuits. This incident highlights the ongoing Wild West in the knockoff GLP-1 market, where unapproved compounded drugs flood the scene despite resolved shortages. Patients risk ineffective or unsafe products—here's what you need to know.
5 min read
Semaglutide: Artificial Shortage as Novo Nordisk's Business Model?
Novo Nordisk's lawsuit against Hims & Hers claims compounded semaglutide sales are illegal now that shortages ended. But is this about patient safety or enforcing high prices like $150/month for Wegovy pills versus $50 alternatives? Dive into how patents create artificial semaglutide shortages.
5 min read
Knockoff GLP-1 Market Still the Wild West: Hims Fallout
Telehealth firm Hims & Hers sparked chaos by launching a cheap compounded Wegovy pill, only to yank it days later amid FDA crackdowns and a Novo Nordisk lawsuit. This incident highlights the ongoing Wild West in the knockoff GLP-1 market. Despite resolved shortages for Wegovy and Zepbound, unregulated compounded drugs remain widely available.
5 min read
Novo Nordisk Sues Hims & Hers Over Semaglutide Patent
Novo Nordisk has filed a lawsuit against Hims & Hers Health Inc., accusing the telehealth company of breaching its U.S. patent on semaglutide used in blockbuster obesity drugs like Ozempic and Wegovy. Despite Hims scrapping plans for a copycat Wegovy pill, Novo claims the compounded versions remain dangerous and infringing. This legal battle highlights growing tensions over compounded GLP-1 drugs post-shortage.
5 min read
Hims & Hers Shares Sink 16% as FDA Halts Wegovy Copycat Pill
Hims & Hers Health Inc. (HIMS) has halted sales of its copycat Wegovy weight loss pill just two days after launch, leading to a 16% plunge in shares amid FDA warnings and Novo Nordisk threats. This marks a regulatory pivot as GLP-1 shortages ease. Patients and investors should note the growing scrutiny on compounded versions of popular drugs like Wegovy.
5 min read
GLP-1 Envy Was Just the Beginning: Hims & Hers Super Bowl Ad
A Hims & Hers Super Bowl ad provocatively claims 'Rich people live longer,' selling telehealth access to GLP-1s, peptides, and testosterone like the elite. But as compounded drugs face DOJ scrutiny, is this democratizing care or risking safety? Dive into the ad, cultural envy, and expert concerns.
5 min read
Hims Stops Compounded Wegovy Pill After FDA Scrutiny
Telehealth giant Hims & Hers has abruptly stopped offering its newly launched compounded version of Novo Nordisk's Wegovy pill amid FDA scrutiny. The decision follows constructive industry conversations, raising questions about compounded GLP-1 availability. Patients seeking semaglutide for weight management now face shifting options.
5 min read
Weight-Loss Price Wars Upend Big Pharma's Model
Two years ago, GLP-1 prescriptions cost over $1,000 monthly for uninsured patients. Now, Wegovy's pill starts at $149, flipping Big Pharma's playbook amid fierce price wars. As Novo Nordisk forecasts sales drops and Eli Lilly surges, discover how consumer demand is reshaping obesity treatments.
6 min read
Weight-Loss Drugs Compete in Super Bowl Ads: Wegovy Leads
Weight-loss drugs like Wegovy's new pill are making a splash with multimillion-dollar Super Bowl ads featuring Kenan Thompson, DJ Khaled, and Serena Williams. As Novo Nordisk and Eli Lilly battle for market share, affordable oral GLP-1 options starting at $49 signal a new era in obesity care. See how these celebrity spots aim to reach 130 million viewers.
5 min read
HIMS Shares Sink After FDA Vows Swift Action on Copycat GLP-1 Drugs
Hims & Hers Health's bold launch of a $49-per-month copycat GLP-1 pill to rival Wegovy's $149 price tag backfired spectacularly. FDA Commissioner Marty Makary vowed 'swift action' against such unapproved drugs, sending HIMS shares down 7.5% in premarket trading. This regulatory showdown highlights growing tensions in the GLP-1 market dominated by Novo Nordisk and Eli Lilly.
4 min read
Eli Lilly Shares Face Pressure Amid GLP-1 Market Shifts
Eli Lilly posted blockbuster Q4 2025 results with $19.29B revenue, yet shares near $1,020 face selling pressure from compounded semaglutide competition and government pricing initiatives. Hims & Hers' $49 pill undercuts Zepbound's $299 intro dose, signaling shifts in the GLP-1 market. Investors eye Orforglipron's FDA decision amid pipeline cuts.
5 min read
Hims & Hers $49 Weight-Loss Pill Jolts Industry, Stock Drops
Hims & Hers launched a $49-a-month compounded version of Novo Nordisk's Wegovy, promising affordable GLP-1 weight-loss treatment amid shortages. Yet, despite an initial 14% stock surge, shares closed down 4% as FDA scrutiny loomed. This move highlights tensions in the booming obesity drug market and accessibility challenges for patients.
5 min read
Novo Nordisk Shares Rebound as FDA Targets Illegal Wegovy Copies
Novo Nordisk's shares rebounded 4.7% in early trading on Friday after the FDA vowed to crack down on companies mass-marketing illegal copies of Wegovy. This followed a sharp sell-off triggered by Hims & Hers' launch of a cheap $49 compounded version. Understand the safety risks and what this means for GLP-1 patients seeking approved weight-loss treatments.
5 min read
Super Bowl LX Ads Feature AI, GLP-1 Drugs & Celebs from Clooney to Jenner
Super Bowl LX is set to showcase a surge in GLP-1 weight-loss drug ads from telehealth giants like Ro featuring Serena Williams and Novo Nordisk's Ozempic and Wegovy. With record $8-10M ad slots, health trends dominate alongside AI and celebrity-packed spots with George Clooney and Kendall Jenner. This 'GLP-1 Super Bowl' highlights booming demand for metabolic health solutions.
6 min read
Super Bowl LX Ads Feature AI, Weight-Loss Drugs & Celebs
Super Bowl LX ads are packed with celebrities from Kendall Jenner to George Clooney, cutting-edge AI demos, and a surge in health spots promoting GLP-1 weight-loss drugs like Ozempic and Wegovy. As viewership hits record highs, advertisers are betting big on telehealth and pharma amid booming demand. This preview reveals the trends shaping America's biggest ad showdown.
6 min read
Hims & Hers Scrutiny: Compounded GLP-1 Drug Risks
Hims & Hers investment narrative shifts amid legal scrutiny on compounded GLP-1 agonists. A January 2026 antitrust lawsuit accuses Eli Lilly and Novo Nordisk of blocking compounded Mounjaro and Wegovy. This raises uncertainties for telehealth providers reliant on these affordable weight management options.
2 min read
Are Microdoses of GLP-1s the New Fitness Trend? Weighing Benefits and Risks
More and more fit individuals are turning to microdoses of GLP-1s, drawn by potential health benefits beyond weight loss. While some see it as a proactive approach to longevity, experts caution about the lack of research and potential risks.
8 min read